<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5223">
  <stage>Registered</stage>
  <submitdate>22/10/2014</submitdate>
  <approvaldate>22/10/2014</approvaldate>
  <nctid>NCT02276313</nctid>
  <trial_identification>
    <studytitle>BIOLUX P-III All-Comers Passeo-18 Lux Registry</studytitle>
    <scientifictitle>BIOTRONIK - A Prospective, International, Mulit-centre, Post-market All-comers Registry to Assess the Clinical Performance of the Passeo-18 Lux Paclitaxel Releasing Balloon Catheter in Infrainguinal Arteries - III</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>C1211</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Atherosclerosis</healthcondition>
    <healthcondition>Peripheral Artery Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Passeo-18 Lux

Treatment: devices: Passeo-18 Lux
Endovascular Therapy

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Freedom from Major Adverse Events (MAE) - A composite of freedom from device- and procedure-related mortality through 30 days, freedom from major target limb amputation and clinically driven target lesion revascularization (TLR) within 6 months post-index procedure.</outcome>
      <timepoint>6 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Freedom from clinically-driven Target Lesion Revascularization (TLR)</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Freedom from clinically-driven TLR</outcome>
      <timepoint>6 and 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Freedom from clinically-driven Target Vessel Revascularization (TVR)</outcome>
      <timepoint>6 and 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Primary patency</outcome>
      <timepoint>12 and 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Freedom from MAE</outcome>
      <timepoint>12 and 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in mean Ankle Brachial Index</outcome>
      <timepoint>6, 12 and 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Amputation-free survival</outcome>
      <timepoint>6, 12 and 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Patient-reported outcomes assessment: Pain score, Walking Impairment Questionnaire</outcome>
      <timepoint>6, 12 and 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical Success: Improvement in Rutherford classification compared to the pre-procedure Rutherford classification</outcome>
      <timepoint>6, 12 and 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Device success - Successful delivery, inflation, deflation, and retrieval of the Passeo-18 Lux DRB.</outcome>
      <timepoint>Day 0</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Technical success - Successful completion of the endovascular procedure and immediate morphological success with = 50% residual diameter reduction of the treated lesion as determined by visual estimation</outcome>
      <timepoint>Day 0</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Procedural success - Procedural success is technical and device success without the occurrence of any major adverse events during the hospital stay</outcome>
      <timepoint>Participants will be followed for the duration of hospital stay, an expected average of 1-2 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Age = 18 years or minimum age as required by local regulations

          -  Subject must be willing to sign a Patient Data Release Form or Patient Informed
             Consent where applicable

          -  Lesion(s) in the infrainguinal arteries suitable for endovascular treatment treated
             with or scheduled to be treated with the Passeo-18 Lux drug releasing balloon</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Life expectancy = 1 year

          -  Subject is currently participating in another investigational drug or device study
             that has not reached ist primary endpoint yet

          -  Subject is pregnant or planning to become pregnant during the course of the study

          -  Failure to successfully cross the target lesion with a guide wire (successful crossing
             means tip of the guide wire distal to the target lesion in the absence of flow
             limiting dissections or perforations</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>880</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/02/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Cairns Hospital - Cairns</hospital>
    <hospital>Lake Macquarie Private Hospital - Gateshead</hospital>
    <hospital>Geelong University Hospital - Geelong</hospital>
    <hospital>Hollywood Hospital - Nedlands</hospital>
    <hospital>The Townsville Hospital - Townsville</hospital>
    <postcode> - Cairns</postcode>
    <postcode> - Gateshead</postcode>
    <postcode> - Geelong</postcode>
    <postcode> - Nedlands</postcode>
    <postcode> - Townsville</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Graz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Innsbruck</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Liege</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Tienen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Kolding</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Tampere</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Clermont-Ferrand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Essey Les Nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Grenoble</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lyon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Arnsberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bad Krozingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Giessen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Göttingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Jena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kiel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>München Pasing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Rosenheim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Firenze</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>San Donato Milanese</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Latvia</country>
      <state>Riga</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Kuala Lumpur</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Eindhoven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Tilburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Almada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Slovakia</country>
      <state>Kosice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Badalona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Leganés, Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Lausanne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Lugano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Winterthur</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Biotronik AG</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>BIOLUX P-III is a prospective, international, multi-centre, postmarket all-comers registry to
      collect clinical performance data on the Passeo-18 Lux paclitaxel releasing balloon catheter
      in the treatment of atherosclerotic disease of the infrainguinal arteries.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02276313</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gunnar Tepe, MD</name>
      <address>RoMed Klinikum Rosenheim</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>